Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Heptanoate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 7/20 | 0.72 |
| ▸ | CA1 | P00915 | 1/20 | 0.71 |
| ▸ | CES2 | O00748 | 4/20 | 0.67 |
| ▸ | CES1 | P23141 | 4/20 | 0.67 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8743307 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Stearic Acid SCHEMBL13836877 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Palmitic Acid SCHEMBL141829 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Myristic Acid SCHEMBL360184 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Undecanoate SCHEMBL11343015 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Decanoic Acid SCHEMBL453322 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Stearic Acid SCHEMBL2371 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Arachidic Acid SCHEMBL7629156 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Stearic Acid SCHEMBL9243538 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Lignoceric Acid SCHEMBL262204 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025060941-A1 | METHOD FOR PRODUCING POLYHYDROXYALKANOATE | 清华大学 | 2025-03-27 | — | — | WO | claimed |
| CN-116970659-B | Method for producing polyhydroxyalkanoate | 清华大学 | 2024-02-09 | — | — | CN | claimed |
| US-20180161365-A1 | Phosphate-Binding Magnesium Salts And Uses Thereof | CURRAX PHARMACEUTICALS LLC | 2018-06-14 | — | — | US | claimed |
| US-9889157-B2 | Phosphate-binding magnesium salts and uses thereof | CYPRESS PHARMACEUTICALS, INC. (US) | 2018-02-13 | — | — | US | claimed |
| US-20170202875-A1 | Phosphate-Binding Magnesium Salts And Uses Thereof | WILMINGTON SAVINGS FUND SOCIETY, FSB | 2017-07-20 | — | — | US | claimed |
| US-9610267-B2 | Phosphate-binding magnesium salts and uses thereof | CYPRESS PHARMACEUTICALS, INC. (US) | 2017-04-04 | — | — | US | claimed |
| US-20160256420-A1 | Phosphate-Binding Magnesium Salts And Uses Thereof | WILMINGTON SAVINGS FUND SOCIETY, FSB | 2016-09-08 | — | — | US | claimed |
| US-9339481-B2 | Phosphate-binding magnesium salts and uses thereof | CYPRESS PHARMACEUTICALS, INC. (US) | 2016-05-17 | — | — | US | claimed |
| US-20130004542-A1 | COMPOSITION | INNOVATA LIMITED (GB) | 2013-01-03 | — | — | US | claimed |
| EP-2490670-A2 | COMPOSITION FOR INHALATION | Innovata Limited (GB) | 2012-08-29 | — | — | EP | claimed |
| EP-2416786-A1 | PHOSPHATE-BINDING MAGNESIUM SALTS AND USES THEREOF | Cypress Pharmaceutical, Inc. (US) | 2012-02-15 | — | — | EP | claimed |
| WO-2011048379-A2 | COMPOSITION | INNOVATA LIMITED (GB) | 2011-04-28 | — | — | WO | claimed |
| WO-2010117370-A1 | PHOSPHATE-BINDING MAGNESIUM SALTS AND USES THEREOF | CYPRESS PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | claimed |
| US-20090269399-A1 | PHOSPHATE-BINDING MAGNESIUM SALTS AND USES THEREOF | CYPRESS PHARMACEUTICAL, INC. (US) | 2009-10-29 | — | — | US | claimed |
| US-20250353078-A1 | COMPOUND, MOLDED BODY AND CURED PRODUCT | RESONAC CORP (JP) | 2025-11-20 | — | — | US | disclosed |
| WO-2025060941-A1 | METHOD FOR PRODUCING POLYHYDROXYALKANOATE | 清华大学 | 2025-03-27 | — | — | WO | disclosed |
| EP-4525004-A1 | COMPOUND, MOLDED BODY AND CURED PRODUCT | Resonac Corporation (JP) | 2025-03-19 | — | — | EP | disclosed |
| EP-0458509-A1 | Oxidation-resistant ethylene vinyl alcohol polymer compositions | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-11-27 | — | — | EP | disclosed |
| US-5032632-A | Oxidation-resistant ethylene vinyl alcohol polymer compositions | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-07-16 | — | — | US | disclosed |
| US-4058540-A | FROM A NITROALKYL NITRATE OR NITRO ALCOHOL AND ALKANOIC ACID, CALCIUM OCIDE OR CARBOXYLATE CATALYST | TEXACO INC. (US) | 1977-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130004542-A1 | COMPOSITION | MATR3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IL5 | FABP3 4194/4885CA1 385/4885CES2 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.